Table 4. Distribution of antiretroviral modifications in HIV-infected patients with a first severe episode of neutropenia (n = 134).
| Drug stopped | Distribution of modifications | Total | |||||
|---|---|---|---|---|---|---|---|
| ZDV | D4T | TDF | EFV | NVP | Other | ||
| ZDV | - | 28 (43%) | 30 (46%) | 0 (0%) | 0 (0%) | 7 (11%) | 65 |
| D4T | 11 (61%) | - | 2 (11%) | 0 (0%) | 0 (0%) | 5 (28%) | 18 |
| TDF | 5 (71%) | 2 (29%) | - | 0 (0%) | 0 (0%) | 0 (0%) | 7 |
| EFV | 0 (0%) | 0 (0%) | 0 (0%) | - | 8 (67%) | 4 (33%) | 12 |
| NVP | 0 (0%) | 0 (0%) | 0 (0%) | 26 (81%) | - | 6 (19%) | 32 |
| Total | 16 (12%) | 30 (22%) | 32 (24%) | 0 (0%) | 0 (0%) | 0 (0%) | 134 |
ZDV, zidovudine; 3TC, lamivudine; EFV, efavirenz; D4T, stavudine; NVP, nevirapine; TDF, tenofovir.